We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.63%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$25.6M
Cap. Flow
-$43.5M
Cap. Flow %
-39.89%
Top 10 Hldgs %
43.42%
Holding
74
New
7
Increased
2
Reduced
48
Closed
7

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.22M
2
RXDX
Ignyta, Inc.
RXDX
+$1.38M
3
CKPT
Checkpoint Therapeutics
CKPT
+$1.16M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$987K
5
LOXO
Loxo Oncology, Inc
LOXO
+$765K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.61M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.69M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.62M
4
ALKS icon
Alkermes
ALKS
+$2.41M
5
INCY icon
Incyte
INCY
+$2.22M

Sector Composition

Rank Sector Weight
1 Healthcare 65.96%
2 Miscellaneous 33.66%
3 Real Estate 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
51
Ultragenyx Pharmaceutical
RARE
$1.29B
$382K 0.35%
6,157
-6,044
-50% -$364K
AKBA icon
52
Akebia Therapeutics
AKBA
$257M
$302K 0.28%
21,009
-21,010
-50% -$266K
GRFS
53
Grifois
GRFS
$5.08B
$272K 0.25%
12,885
-9,047
-41% -$190K
IQV icon
54
IQVIA
IQV
$44.5B
$261K 0.24%
2,921
-2,106
-42% -$178K
CRL icon
55
Charles River Laboratories
CRL
$13B
$259K 0.24%
2,562
-1,879
-42% -$173K
LGND icon
56
Ligand Pharmaceuticals
LGND
$5.44B
$257K 0.24%
3,387
-2,575
-43% -$180K
TECH icon
57
Bio-Techne
TECH
$11.3B
$248K 0.23%
8,448
-6,712
-44% -$183K
NBIX icon
58
Neurocrine Biosciences
NBIX
$15.5B
$238K 0.22%
5,175
-4,009
-44% -$194K
GILD icon
59
Gilead Sciences
GILD
$181B
$230K 0.21%
3,256
-2,481
-43% -$165K
HRTX icon
60
Heron Therapeutics
HRTX
$59M
$220K 0.2%
15,874
-15,874
-50% -$230K
IOVA icon
61
Iovance Biotherapeutics
IOVA
$4.1B
$220K 0.2%
29,934
-23,223
-44% -$148K
ICPT
62
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$220K 0.2%
1,820
-1,492
-45% -$173K
CFRX
63
DELISTED
ContraFect Corporation
CFRX
$218K 0.2%
188
-187
-50% -$219K
AVXS
64
DELISTED
AveXis, Inc. Common Stock
AVXS
$205K 0.19%
2,500
-2,500
-50% -$187K
SCTL
65
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$177K 0.16%
28,133
-28,133
-50% -$193K
PGNX
66
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$148K 0.14%
21,782
-21,783
-50% -$161K
SCYX icon
67
SCYNEXIS
SCYX
$44.4M
$119K 0.11%
833
-832
-50% -$138K
ACAD icon
68
Acadia Pharmaceuticals
ACAD
$4.64B
– –
-11,130
Closed -$383K
MCRB icon
69
Seres Therapeutics
MCRB
$47M
– –
-700
Closed -$158K
UTHR icon
70
United Therapeutics
UTHR
$21.5B
– –
-2,756
Closed -$373K
PTLA
71
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-25,000
Closed -$980K
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-20,595
Closed -$176K
ALDR
73
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-17,858
Closed -$371K
BIVV
74
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-5,587
Closed -$304K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opus Point Partners Management held 74 positions worth $109M, down 19% from $135M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management withdrew a net $43.5M in Q2 2017, closing 7 positions and reducing 48 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $980K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Ignyta, Inc. worth $1.76M.

  • Opus Point Partners Management's largest Q2 2017 buy was Ignyta, Inc.: 170,500 shares worth $1.76M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2017, an estimated $2.22M increase.
  • Opus Point Partners Management's biggest Q2 2017 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.61M.
  • Opus Point Partners Management fully exited Portola Pharmaceuticals, Inc. in Q2 2017, selling an estimated $980K.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $109M portfolio in Q2 2017.
  • Opus Point Partners Management opened 7 new positions and closed 7 in Q2 2017.
  • Opus Point Partners Management's portfolio value fell 19% quarter-over-quarter to $109M.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.